Pharmamarketeer

Novartis arthritis drug fails to prove it is significantly better than rival

A clinical trial of Novartis’s Cosentyx drug has failed to prove it is significantly better than a rival treatment for a type of arthritis, the Swiss company said on Friday.

Medhc-fases-banner
Advertentie(s)